Analgesic Effect of Fascia Transversalis Block Versus Transversus Abdominal Plane Block in Children Undergoing Open Inguinal Hernia Surgery. A Randomized Comparative Trial.

Fascia transversalis block in pediatrics undergoing inguinal surgical repair may be simple technique and may give longer effect in reduction of post-operative pain in comparison to transversus abdominis plane block.

开始日期2024-01-18

申办/合作机构

Qasr El Eyni Hospital

NCT06172920 / Not yet recruiting临床4期IIT

Comparison of the Analgesic Effects of Tramadol, Pethidine and Morphine Under Erector Spinae Plane (ESP) Block in the Treatment of Pain After Elective Thoracic Surgery

Comparison of analgesic effects of tramadol, aldolan and morphine under thoracic surgery

开始日期2023-12-31

申办/合作机构

Baskent University

100 项与盐酸哌替啶相关的临床结果

登录后查看更多信息

100 项与盐酸哌替啶相关的转化医学

登录后查看更多信息

100 项与盐酸哌替啶相关的专利（医药）

登录后查看更多信息

5,826

项与盐酸哌替啶相关的文献（医药）

2024-04-01·Anaesthesia

The association between epidural labour analgesia and postpartum depression: a randomised controlled trial

Article

作者: Sng, B L ; Rahman, N ; Sultana, R ; Tan, H S ; Chen, H Y ; Tan, C W ; Sia, A T H ; Gandhi, M ; Chua, T

Summary:

There is conflicting evidence regarding the association between epidural labour analgesia and risk of postpartum depression. Most previous studies were observational trials with limited ability to account for confounders. We aimed to determine if epidural analgesia was associated with a significant change in the incidence of postpartum depression in this randomised controlled trial. We enrolled women aged 21–50 years old with a singleton fetus ≥ 36 weeks gestation. Patients were advised regarding available labour analgesic modalities during enrolment (epidural block; intramuscular pethidine; nitrous oxide; or intravenous remifentanil). On request for analgesia, patients were offered the modality that they had been allocated randomly to first. Blinded investigators recorded patient and obstetric characteristics within 24 h of delivery and assessed for postpartum depression at 6–10 weeks following delivery using the Edinburgh Postnatal Depression Scale (score ≥ 13 considered positive for postpartum depression). The modified intention‐to‐treat population consisted of all patients who received any form of labour analgesia, while per‐protocol consisted of patients who received their randomised modality as their first form of labour analgesia. Of 881 parturients allocated randomly (epidural n = 441, non‐epidural n = 440), we analysed 773 (epidural n = 389, non‐epidural n = 384); 62 (15.9%) of women allocated to epidural group developed postpartum depression compared with 65 (16.9%) women allocate to the non‐epidural group. There were no significant differences in the incidence of postpartum depression between the two groups (adjusted risk difference (95%CI) 1.6 (‐3.0–6.3%), p = 0.49). Similar results were obtained with per‐protocol analysis (adjusted risk difference (95%CI) ‐1.0 (‐8.3–6.3%), p = 0.79). We found no significant difference in the risk of postpartum depression between patients who received epidural labour analgesia and those who utilised non‐epidural analgesic modalities.

2024-02-01·The journal of allergy and clinical immunology. Global

Drug-induced hypersensitivity reactions in a Lebanese outpatient population: A decade-long retrospective analysis (2012-2021)

Article

作者: de Chaisemartin, Luc ; Chollet-Martin, Sylvie ; Pallardy, Marc ; Azouri, Hayat ; Dagher, Joelle ; Antonios, Diane ; Irani, Carla

Background:

Drug hypersensitivity reactions (DHRs) are becoming more common as a result of increasing prevalence and case complexity. Allergists and clinical immunologists worldwide are challenged daily to adequately diagnose and manage these reactions. Data in the literature regarding DHR outpatient consultations are scarce worldwide, limited in the Middle East, and currently unavailable in Lebanon.

Objective:

This retrospective study aimed to evaluate the characteristics of all reported DHRs over 10 years in a tertiary-care allergy clinic in Lebanon.

Methods:

We conducted a decade-long (2012-21) retrospective analysis of the archived medical records of patients with a history of DHRs. Demographics, clinical history, diagnostic tools, and characteristics of the DHRs were collected and analyzed.

Results:

A total of 758 patients experienced DHRs to therapeutic molecules provided for ambulatory care. Our results identified 72 medications. The most frequently implicated drug classes included β-lactam antibiotics (53.8%), followed closely by nonsteroidal anti-inflammatory drugs (48.9%). Of the 758 patients, 32.6% reported DHRs to multiple molecules, and 11.8% reported concomitant DHRs to 1 or several molecules provided in the perioperative setting. Of those, opioids and neuromuscular blocking agents were the 2 most common therapeutic classes. Furthermore, we evaluated the cross-reactivity between molecules of the same class. In neuromuscular blocking agents, rocuronium and cisatracurium were the most commonly cross-reactive, and for opioids, the most common association we recorded was with morphine and pethidine.

Conclusion:

Our findings constitute the first step toward a more comprehensive evaluation of the clinical characteristics of DHRs in Lebanon.

2024-02-01·Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostation, octreotide and cyclooxygenase-2 inhibitors

Article

作者: Wang, Rui ; Gong, Hui ; Tang, Cheng-Wei ; Huang, Zhi-Yin ; Wang, Mo-Jin

BACKGROUND:

/Objectives: Persistent organ failure (OF) in severe acute pancreatitis (SAP) is caused by activation of cytokine cascades, resulting in inflammatory injury. Anti-inflammation may be helpful in OF remission in early SAP. To assess the efficacy of anti-inflammatory regimens for OF prevention and remission in patients with predicted SAP and display clinical doctors' acceptance of these strategies, we conducted this retrospective study in the real world.

METHODS:

Clinical data of patients with predicted SAP from 2010 to 2017 were retrospectively reviewed. Cases were divided into conventional support (C), C+ somatostatin/octreotide (C + S/O), and C + S/O + Cyclooxygenase-2-inhibitors (C + S/O + COX-2-I). The occurrence of SAP, OF, changes of proportion for three strategies, length of hospital stay, meperidine injection, and cytokine levels were compared. The constituent ratios of the three schemes over eight years were evaluated.

RESULTS:

A total of 580 cases (C = 124, C + S/O = 290, C + S/O + COX-2-I = 166) were included. The occurrences of SAP in the C + S/O (28.3 %) and C + S/O + COX-2-I (18.1 %) groups were significantly lower than that in C group (60.5 %, P < 0.001), mainly by reducing persistent respiratory failure (P < 0.001) and renal failure (P = 0.002). C + S/O and C + S/O + COX-2-I regimens significantly decreased new onset OF and enhanced OF amelioration within 48 h when compared with C treatment (P < 0.001) in patients with OF score <2 and ≥ 2 on admission, respectively. C + S/O and C + S/O + COX-2-I as compared with C group significantly decrease OF occurrences in a multivariate logistic regression analysis (P < 0.05).

CONCLUSIONS:

Somatostatin or its analogs and cyclooxygenase-2 inhibitors are promising for OF prevention and remission in patients with predicted SAP. The acceptance of combined strategies in the real world has increased, and the occurrence of SAP has decreased annually.

项与盐酸哌替啶相关的新闻（医药）

2024-04-11

·梅斯医学

世界帕金森病日：关注年轻帕金森病群体

2024年4月11日是第28个世界帕金森病日，今年的主题是：和谐共生，美好生活。帕金森病又称为震颤麻痹，是常见的神经系统退行性病变。现代流行病学调查显示，我国65岁以上人群患病率为1.7%。在中国人口老龄化背景下，PD的发病率又有着随年龄增长而上升的特点。我国大约有超过300万的帕金森病患者，预计到2030年，中国帕金森病患者将达到490万（全球约870万）。帕金森病是一种常见的发生于老年人的神经系统退行性疾病，但是该病也会影响青少年和青年人群，出现罕见的早发型帕金森病（EOPD），约占所有帕金森病的5-10%。早发型帕金森病根据发病年龄又可进一步分为：青年型帕金森病（YOPD）：发病年龄21-50岁；青少年型帕金森病（JP）：发病年龄＜21岁。病因1、遗传因素早发型帕金森病具有明确的遗传易感性和家族聚集性，多数具有阳性家族史，提示遗传因素在其中起到重要作用。目前已有20多个基因明确定位，包括常染色体显性和隐性遗传两种主要遗传方式。常见的常染色体显性遗传基因：SNCA、LRRK2、UCH-L1、VPS35等。常见的常染色体隐性遗传基因：Parkin、PINK1、DJ-1、ATP13A2、PLA2G6等。易感基因：不直接致病，在正常人群中也可检出，但是其存在增加PD的发生风险，例如GBA、MAPT、SNCA等。多个易感基因携带者发生PD的风险显著增高，提示多个微效基因的叠加效应。此外，易感基因之间还存在交互作用。2、心理因素近年来，随着升学和就业压力逐渐增加，青少年型帕金森病在生活中出现得越来越频繁。医学界普遍认为，帕金森病跨年龄发病的病因与心理压力也有关联。 3、其他EOPD还常常与病毒性脑炎、脑外伤、一氧化碳中毒以及药物滥用有关。其中，吸毒引发EOPD病例虽然不多，但也需要引起足够的重视。早在1976年就已发现，在非法合成毒品MPPP（一种类似于吗啡和哌替啶的毒品）时，可以意外生成一种杂质MPTP，后者被证实为能够破坏黑质多巴胺能神经元的神经毒素，这种神经毒素至今仍广泛用于帕金森动物模型的研究中。另外，也有数据显示苯丙胺和甲基苯丙胺（冰毒）均可增加帕金森病的发病风险。临床表现EOPD的临床表现包括运动症状和非运动症状。1、运动症状EOPD的首发症状以运动迟缓多见，也可以肌张力障碍为首发症状。EOPD以强直少动症状为主要表现，静止性震颤、早期平衡功能障碍相对少见；部分患者可伴有肌张力障碍，多见于足部或下肢的局灶型肌张力障碍，通常表现为模式化的扭曲动作，可以呈现震颤样，且可被随意动作诱发或加重。2、非运动症状包括神经精神症状、睡眠障碍、认知功能障碍、便秘等，以抑郁、不宁腿综合征、成瘾行为较多见，而认知功能障碍、神经精神症状、幻觉等相对少见，嗅觉功能相对保留较好。诊断根据发病年龄≤50岁，必备运动迟缓及至少具备静止性震颤或肌强直中的一项，参照《中国帕金森病的诊断标准(2016版)》诊断EOPD：抗帕金森病药物治疗1、左旋多巴制剂：如多巴丝肼、卡左双多巴控释片、左旋多巴/卡比多巴肠内凝胶等。EOPD患者对左旋多巴制剂的反应良好，左旋多巴制剂可显著改善运动症状，但相对容易出现运动并发症。针对伴有智能减退的EOPD患者，一般首选左旋多巴制剂进行治疗；针对力求显著改善运动症状的EOPD患者，一般选择左旋多巴制剂或左旋多巴制剂联合儿茶酚-O-甲基转移酶（COMT）抑制剂进行治疗。注意：对于25岁以下，特别是青少年期及儿童期患者，由于左旋多巴制剂会影响骨骼发育，因此不推荐使用。2、非麦角类DR激动剂：如吡贝地尔、普拉克索、罗匹尼罗、罗替高汀等，可作为不伴智能减退的EOPD患者的单药治疗药物。适用于病程初期的EOPD患者，但较易出现与非麦角类DR激动剂相关的发作性睡眠及冲动控制障碍。注意：对于青少年期患者应慎用，儿童期患者不推荐使用。3、MAO-B抑制剂：如司来吉兰和雷沙吉兰，亦可作为不伴智能减退的 EOPD 患者的单药治疗药物；也可作为左旋多巴制剂的联合药物，特别是对于症状波动的EOPD患者。注意：对于青少年期患者及儿童期患者不推荐使用。4、COMT抑制剂：如恩他卡朋、恩他卡朋双多巴等。恩他卡朋可与多巴丝肼等左旋多巴制剂联合用药，可提高左旋多巴的生物利用度，延长左旋多巴的临床疗效，改善EOPD患者的运动症状。注意：对于青少年期患者及儿童期患者不推荐使用。5、抗胆碱能药物：如苯海索，对EOPD患者的静止性震颤有效，无静止性震颤的EOPD患者不予推荐。注意：长期服用可导致认知功能损害。对于青少年期及儿童期患者应慎用。6、金刚烷胺：对运动迟缓、肌强直有一定作用，对改善异动症有一定帮助。注意：对于青少年期患者应慎用，儿童期患者不推荐使用。参考文献：[1]中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍学组. 早发型帕金森病的诊断与治疗中国专家共识（2021）[J]. 中华神经医学杂志，2021,20 (2)：109-116.[2]中国帕金森病的诊断标准(2016版)撰文 | Anna.An编辑 | Swagpp● 延寿7-8年，还能抗癌！两次登上顶刊：饮料中这种常见成分，还能增强癌症治疗的疗效！● 每周“洗脑”30分钟，让大脑返老还童？Nature最新：改善老年的认知能力，还能缓解阿尔茨海默症的病理！但要注意...● 热议！“交了护理费凭啥还要再花380元请护工？”患者要求取消护工：太贵且不负责，适当提高护理费，护士为啥就不能照顾病人拉屎撒尿？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

核酸药物

2023-12-18

·药研网

「 IL-2 」治疗肿瘤和自身免疫疾病的重要方向之一

白细胞介素 (IL)简称白介素，是由多种细胞产生并作用于多种细胞的一类细胞因子（Cytokine）。白介素功能复杂，形成网络，复杂重叠，在免疫细胞的成熟、活化、增殖和免疫调节等一系列过程中均发挥重要作用，此外它们还参与机体的多种生理及病理反应。IL-2是对免疫系统具有多效作用的关键细胞因子之一，曾以胸腺细胞刺激因子（Thymocyte stimulating factor，TSF）、T细胞生长因子（T cell growth factor,TCGF）等称之。IL-2概述IL-2 分子量 15.5kDa，是一条单链的多肽分子。IL-2主要由CD4+T细胞通过T细胞受体(TCR)和CD28共刺激信号激活后分泌。CD8+T细胞、NK细胞、自然杀伤T细胞(NKT)和树突状细胞也产生IL-2，但数量较少。IL-2通过与其受体结合，发挥信号调节作用。IL-2受体主要由IL-2Rα(CD25)、IL-2Rβ(CD122)、 IL-2Rγ(CD132)三种亚基组成。IL-2Rγ/CD132在所有淋巴细胞上表达，而IL-2Rβ/CD122在自然杀伤（NK）和CD8记忆T细胞上组成型表达，并且可以在抗原识别后在幼稚T细胞上诱导。IL-2Rγ/CD132和IL-2Rβ/CD122能够进行细胞内信号传导的亚基，而IL-2Rα/CD25不参与信号传导。低浓度的IL-2优先结合在Treg上组成型表达的高亲和力三元复合物受体（IL2Rαβγ），因此低剂量IL-2可激活Treg来诱导免疫耐受，用于治疗1型糖尿病，红斑狼疮等自身免疫性疾病的治疗。高浓度的IL-2饱和Treg之后会结合比如NK细胞和CD8+T细胞上组成型表达的中等亲和力的二元复合物受体（IL2Rβγ），激活NK细胞和CD8+T细胞，增加抗癌活性。而在IL-2Rα/CD25亚基单独存在时，其与IL-2的亲和力只有三元复合物受体（IL2Rαβγ）的百分之一。因此不同的研发公司根据不同的应用场景进行了不同设计方法的探索，包括PEG化修饰、融合Fc、突变体设计、双特异性抗体设计、联合免疫检查点抗体用药等策略。IL-2的信号通路IL-2通过IL-2Rβ和γc的细胞质结构域的异源二聚发出信号，引起至少三个主要的信号通路被激活：磷酸肌醇3-激酶（PI3-K）/AKT、Ras-MAP激酶和JAK-STAT通路（主要是JAK1、JAK3；STAT5A和STAT5B；尽管STAT3和STAT1也可以被激活）（图1）。这三条信号通路共同介导细胞生长、存活、分化和免疫密切相关。图1.IL-2 信号通路其它几个因子的信号通路类似于此。不过STAT利用倾向略异。目标细胞略有不同。IL-2、IL-7、IL-9和IL-15主要激活STAT5A和STAT5B（统称为STAT5），而IL-4通常激活STAT6，IL-21主要激活STAT3。激活的STAT蛋白的不同可能是这些细胞因子作用有异的原因之一。IL-2的主要生物学活性图2. IL-2的主要生物学活性1、刺激T细胞生长各种刺激物活化的T细胞一般不能在体外培养中长期存活，加入IL-2则能使其长期持续增殖，因此IL-2曾被命名为T细胞生长因子（T cell growth factor，TCGF）。静止的T细胞表面不表达IL-2R，对IL-2没有反应；受丝裂原或其它刺激活化后T细胞才能表达IL-2R，成为IL-2的靶细胞；而IL-2又可诱导靶细胞增加IL-2R的表达。在活体内，IL-2对CD4+ T细胞的作用是通过自分泌途径实现的，因为活化的CD4+ T细胞能够产生大量的IL-2；而CD8+ T细胞则通过旁分泌途径来维持细胞的生长。IL-2R在T细胞上的表达是一次性的，一般在活化后2～3天达到高峰，6～10天左右消失。随着IL-2R的消失，T细胞即失去对IL-2的反应能力。因此若要维持正常T细胞在体外长期生长，必须不断地用丝裂原或其它刺激物去刺激T细胞，以维持IL-2R的表达。2、诱导细胞毒作用①接受了预刺激信号的CD8+ T细胞可以受IL-2的作用活化为CTL，发挥细胞毒作用；在一定条件下，CD4+ T细胞也可受IL-2的诱导而具有杀伤作用。②NK细胞是唯一正常情况下表达IL-2R的淋巴样细胞，因此始终对IL-2保持反应性。然而静止的NK细胞上只表达IL-2R的β链和γ链，对IL-2的亲和力低，只能对高浓度的IL-2发生反应。一旦NK细胞活化，就表达IL-2R的α链，成为高亲和力的受体；大剂量的IL-2诱导的LAK活性主要是NK细胞。③使T细胞和NK细胞产生IFN-γ、TNF-β和TGF-β等因子，促进非特异性细胞毒素；还可诱导产生某些B细胞生长因子以及造血生长因子等，从而发挥相应的生物学作用。3、对B细胞的作用IL-2对B细胞的生长及分化均有一定的促进作用。活化的或恶变的B细胞表面表达高亲和力IL-2R，但是密度较低；较高密度的IL-2可诱导B细胞生长繁殖，促进抗体分泌，并诱使B细胞由分泌IgM向着分泌IgG2转换。4、对巨噬细胞的作用人类单核－巨噬细胞表面在正常时有少量的IL-2Rβ链表达，但是受到IL-2、 IFN-γ或其它活化因子作用后，可表达高亲和力IL-2R。单核－巨噬细胞受到IL-2的持续作用后，其抗原递呈能力、杀菌力、细胞毒性均明显增强，分泌某些细胞因子的能力也得到加强。IL-2靶点药物布局免疫系统可以对抗肿瘤细胞，这一点早已证实。IL-2是第一种成功应用于癌症患者治疗的细胞因子。这是因为它不仅可以促进NK细胞，还能促进T细胞，诱导和增强细胞毒活性。在过去20年中，IL-2在不影响T细胞活性的情况下扩展T细胞的潜力，使得它作为癌症患者免疫治疗剂的作用得到确认。20世纪90年代，许多企业开始发力工程化IL-2，作为最早被批准的抗肿瘤药物之一，早期的第一代IL-2药物存在诸多问题，IL-2的副作用引起人们注意：IL-2可引起发热、呕吐等一般症状，还可导致水盐代谢紊乱和肾、肝、心、肺等功能异常；最常见、最严重的是毛细血管渗漏综合征，使患者不得不终止治疗。IL-2的副作用常与IL-2的剂量及用药时间呈相关，停止用药后症状多迅速减轻或消失。IL-2引起副作用的机制是多方面的，但主要是间接性的，即IL-2诱导产生的某些因子或杀伤性细胞起着重要作用；现已知LAK细胞可通过溶解血管内组织而导致多种副作用。给予适当药物（如吲哚美辛、哌替啶、对乙酰基氨酚等）、采取联合用药、改进给药方式（如少量多次短时间输注）和给药途径（如改全身用药为肿瘤局部用药）等将有效地减轻不良反应。为了增加IL-2药物的成药几率，下一代在研的IL-2药物有多种方向，如：化合物修饰，分子突变及改造等。其中的热点方向是开发针对性的IL-2R偏向激动剂，通过偏向性调节不同信号受体亚基对不同种类的T细胞（Treg，Teff和NK等）的特异性刺激以达到降低药物副作用，扩大适应症范围的目的。从IL-2药物全球进展来看，安进，默沙东，艾伯维、赛诺菲和Citius等企业均有布局；而国内企业也不甘示弱，恒瑞、信达、君实、先声药业和迈威生物等企业纷纷加入。截至目前全球已有5款IL-2药物获批上市，IL-2相关药物研发进展具体信息见下表：（注：本文相关分析是基于公开资料整理，可能存在不全情况，有漏缺的欢迎后台私信补充。）总的来说，现阶段IL-2相关药物研发方向多样，进展快速，是目前正在开发的基于细胞因子的免疫疗法中的重要方向之一。基于 IL-2R 不同功能开发的药物为治疗肿瘤和自身免疫疾病患者带来极大希望。参考资料：【1】https://en.wikipedia.org/wiki/Interleukin【2】https://doi-org.libproxy1.nus.edu.sg/10.1080/2162402X.2016.1163462【3】https://www.rndsystems.com/cn/pathways/il2-signaling-pathways细胞系产品查询投稿丨商务合作转载丨加交流群往期推荐恒瑞医药生物药管线全梳理中生制药企业梳理石药集团生物药技术平台及管线梳理国内ADC热门靶点竞争格局一览点击下方“药研网”，关注更多精彩内容

细胞疗法临床结果临床研究

2023-12-11

·BioSpace

Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions

VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / Wex Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has commenced its Quantitative Sensory Testing (QST) clinical trial and is actively recruiting participants into this clinical trial. The QST clinical trial is being conducted in the Netherlands on 25 healthy volunteers, where each volunteer will receive two different doses of Halneuron. The primary objective is to evaluate the effect on the peripheral nervous system when different doses of TTX are administered to healthy volunteers. Sensitivity and pain from cold, heat, touch, vibration, and smell will be assessed. Mr. Walter Korz, Chief Executive Officer of WEX says, "Quantifying the impact of TTX on a healthy person's sensory perceptions will help us further understand how and why TTX uniquely relieves pain differently from common pain therapies used today. The QST clinical trial will also help us to better understand how TTX can be used in a more personalized manner to enhance its effectiveness for pain management." This is the first time Halneuron® will be evaluated in Europe. WEX has received EMA approval to conduct this clinical trial including obtaining necessary permits to import Halneuron into Europe. About Quantitative Sensory Testing (QST) QST is a sensitive, validated measure for peripheral sensory nervous function. The QST clinical trial involves stimulating a person's skin with quantified sensory stimuli to determine thresholds and other changes in their sensory perception and sensory function. Heat and cold responses provide information about the function of thinly myelinated Aδ nerve fibers, light touch and vibration responses provide information about large myelinated Aβ nerve fibers, and a pain response indicates an impact on unmyelinated C fibers. About Halneuron® Halneuron® (TTX, Tetrodotoxin), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels and/or by blocking ectopic discharges associated with chronic pain. Halneuron® is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. Halneuron does not cross the blood-brain barrier and, therefore, is without the common side effects of euphoria, addiction, tolerance, sedation, and confusion experienced by opioids and other analgesics. Pharmacology studies revealed that TTX is a more potent analgesic than standard analgesic agents such as aspirin, morphine, or meperidine, with potential applications in many moderate to severe neuropathic pain conditions. About WEX Pharmaceuticals Inc. WEX Pharmaceuticals Inc. is a late-stage drug development company dedicated to the development, manufacture, and commercialization of innovative drug products to treat pain. WEX is a leader in research in the field of sodium channel blockers and has programs in various stages of development based on the Halneuron® platform. WEX has conducted late-stage multinational clinical trials in cancer pain and chemotherapy-induced neuropathic pain. WEX is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CKLS"). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing, sale of, and investment in products and assets which fall into three core categories - nutraceuticals, pharmaceuticals & diagnostics, and agriculture-related. CKLS is a member of the CK Hutchison Group. For additional information, please visit . This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information under applicable Canadian securities laws (collectively "forward-looking statements"), including statements regarding the safety and therapeutic utility of Halneuron® as a peripheral-acting, non-opioid analgesic. Statements in this document regarding future expectations, beliefs, goals, plans, or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", "reduces," "affirms", "acceptable", "accepts", "establishes", "continued advancement", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to: those associated with the success of research and development programs, the Company's ability to raise additional funding and the potential dilutive effects thereof, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are developed based on assumptions about such risks, uncertainties and other factors, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, TTX is a more potent analgesic than standard analgesics, safety of product, effectiveness of drug, general business and economic conditions, the Company's ability to successfully develop and commercialize new products, the assumption that the Company's current good relationships with third parties will be maintained, the availability of financing on reasonable terms, the Company's ability to attract and retain skilled staff, market competition, the products and technology offered by the Company's competitors, no known competing drugs specifically for CINP, and the Company's ability to protect patents and proprietary rights. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For further information contact: WEX Pharmaceuticals Inc. Mr. Walter Korz Chief Executive Officer Phone: (604) 683-8880 Fax: (604) 683-8868 E-mail: wex@wexpharma.com Internet: SOURCE: WEX Pharmaceuticals Inc. View the original press release on accesswire.com

临床研究

100 项与盐酸哌替啶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01383	盐酸哌替啶	N02AB02	DB00454

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	Hospira, Inc.	1942-11-10
麻醉引起的产科并发症	美国	Hospira, Inc.	1942-11-10
疼痛	美国	Validus Pharmaceuticals LLC	1942-11-10
疼痛	美国	Hospira, Inc.	1942-11-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02486328 (CTgov)	临床4期	胃肠功能紊乱 \| 认知	103	meperidine+Midazolam (Group MM)	壓糧衊獵淵鹹鑰壓鏇鏇(廠範獵構積構繭繭構製): P-Value = 0.001 更多	-	2020-09-03
				Propofol+Remifentanil (Group RP)
NCT02494180 (CTgov)	临床4期	疼痛 \| 不孕	170	fentanyl+Midazolam (A: Intravenous Fentanyl, Midazolam)	廠夢艱艱範糧鬱膚遞繭(範製壓衊網壓網廠壓願) = 糧願鬱鬱艱鏇網繭淵顧顧鬱衊遞簾襯淵淵網齋 (壓淵鬱衊鑰構壓範製壓, 選餘簾鹽鬱繭鹹願範網 ~ 積積願選顧獵鏇壓顧網) 更多	-	2019-03-05
				pethidine+Diazepam (B: Intravenous Pethidine, Diazepam)	廠夢艱艱範糧鬱膚遞繭(範製壓衊網壓網廠壓願) = 鏇築醖獵鬱蓋壓網憲簾顧鬱衊遞簾襯淵淵網齋 (壓淵鬱衊鑰構壓範製壓, 醖餘襯憲製醖繭選網製 ~ 築窪範願壓憲鹹餘願鹹) 更多
NCT01741259 (CTgov)	N/A	镇痛	273	Meperidine (Meperidine PCEA)	願夢鏇鹹襯窪範製選鹽(願齋餘淵鹽窪艱築範鑰) = 鑰獵鬱選齋遞鹽窪壓廠願醖醖窪築鑰衊築願構 (糧範艱齋糧憲壓構醖築, 網選繭廠簾醖簾廠窪鑰 ~ 範鹽廠齋醖願窪衊鑰夢) 更多	-	2017-10-25
				Meperidine (Meperidine PCEA With Basal)	願夢鏇鹹襯窪範製選鹽(願齋餘淵鹽窪艱築範鑰) = 憲鏇鑰範築衊襯繭夢觸願醖醖窪築鑰衊築願構 (糧範艱齋糧憲壓構醖築, 夢艱網壓範壓壓襯構糧 ~ 積廠獵簾鹽範選鏇窪築) 更多
NCT02027311 (CTgov)	临床4期	胆管上皮癌 \| 胰腺炎 \| 胰腺癌 ... 更多	63	Meperidine+Etomidate (Etomidate)	醖鹹築廠願觸鹹鏇網鹹(獵範廠糧鹽觸淵夢鏇獵) = 遞艱襯製選觸艱餘齋鑰顧鹽鹽壓積鏇衊憲壓齋 (範遞膚夢獵鹽鏇醖衊構, 艱築壓繭醖餘衊夢糧製 ~ 蓋遞積齋範餘觸壓簾網) 更多	-	2015-06-29
				Meperidine+Midazolam (Midazolam)	醖鹹築廠願觸鹹鏇網鹹(獵範廠糧鹽觸淵夢鏇獵) = 衊艱獵觸範願艱鑰糧衊顧鹽鹽壓積鏇衊憲壓齋 (範遞膚夢獵鹽鏇醖衊構, 鬱餘廠醖蓋鹹顧窪齋齋 ~ 膚築衊製網積鹹構網獵) 更多
Pubmed \| BJOG	N/A	产痛	-	s.c. fentanyl	餘築選廠網膚鏇鑰獵鬱(鬱夢憲積鑰鏇獵網範廠) = shorter by at least 2 hours 構顧夢餘鹹窪糧襯鬱範 (襯鬱製製選夢膚廠夢艱 )	-	2015-06-01
				i.n. fentanyl
NCT01709422 (CTgov)	临床4期	胆囊疾病	140	Meperidine+Propofol+Midazolam (Propofol,Midazolam and Meperidine)	鑰獵窪遞觸廠築糧淵鬱(衊鏇顧憲願鬱糧願憲醖): Mean Difference (Final Values) = 28 (95% CI), P-Value = 0.05 更多	-	2013-08-27
				Meperidine+Midazolam (Midazolam and Meperidine)
NCT01555671 (Pubmed \| Eur J Obstet Gynecol Reprod Biol)	临床4期	-	250	Pethidine	膚憲簾淵獵襯製遞獵鑰(簾獵窪膚鹽淵鏇製選鏇): OR = 8.59 (95% CI, 3.29 ~ 22.46)	不佳	2006-12-01
				Placebo